반응식
[NH2:1][C:2]1[CH:3]=[N:4][CH:5]=[CH:6][C:7]=1[C:8]1[N:17]=[CH:16][C:15]2[N:14]([CH3:18])[C:13](=[O:19])[C@@H:12]([CH2:20][CH3:21])[N:11]([CH:22]([CH3:24])[CH3:23])[C:10]=2[N:9]=1.[CH3:25][S:26](Cl)(=[O:28])=[O:27].C(O)(C(F)(F)F)=O>>[CH2:20]([C@H:12]1[N:11]([CH:22]([CH3:23])[CH3:24])[C:10]2[N:9]=[C:8]([C:7]3[CH:6]=[CH:5][N:4]=[CH:3][C:2]=3[NH:1][S:26]([CH3:25])(=[O:28])=[O:27])[N:17]=[CH:16][C:15]=2[N:14]([CH3:18])[C:13]1=[O:19])[CH3:21]참가 물질
4
실험 절차
The title compound was prepared similarly to the methods described in Example 114, with (R)-2-(3-aminopyridin-4-yl)-7-ethyl-8-isopropyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Example 93) instead of (R)-2-(3-aminopyridin-4-yl)-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one (Example 91) and with methane sulfonylchloride instead of chloromethylcarbonate. LCMS (0.05% TFA): 405.2 m/z (M+H)+; 1H-NMR (DMSO-d6, 500 MHz): δ: 12.77 (bs, 1H), 8.89 (bs, 1H), 8.50 (bs, 1H), 8.41 (s, 1H), 8.23 (s, 1H), 4.55 (m, 1H), 4.49 (m, 1H), 3.34 (s, 3H), 3.26 (s, 3H), 1.87 (m, 1H), 1.77 (m, 1H), 1.44 (bs, 6H), 0.75 (bs, 3H).
출처 및 근거
- ORD 기록
- ord-7c0df9caca7445d1be2ab0ef8fcab4b0
- 출처 데이터셋
- uspto-grants-2013_09
- 특허 번호
- US08541418B2
연결된 노트
불러오는 중…